Substituted Heterocycle Fused Gamma-Carboline for Selective 5-HT2A Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for central nervous system disorders, particularly those involving the 5-HT2A receptor and dopamine D1/D2 receptor signaling systems, often come with side effects such as drug dependency, muscle hypotonia, and other adverse effects due to high occupancy of dopamine D2 pathways, limiting their efficacy and safety.
Innovation Solution
Development of a compound, specifically a substituted heterocycle fused gamma-carboline, which acts as a potent serotonin 5-HT2A receptor antagonist with moderate D1 receptor modulation and weak D2 receptor activity, minimizing SERT activity and mu-opiate receptor interaction, thereby reducing side effects associated with conventional sedative-hypnotic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional sedative-hypnotic agents are used to treat central nervous system disorders, then they can achieve therapeutic effects, but they cause side effects such as drug dependency, muscle hypotonia, and other adverse effects due to high occupancy of dopamine D2 pathways
Solution Approach 1:
The patent applies local quality by designing a compound with selective receptor affinity profiles. The compound exhibits potent 5-HT2A antagonism (Ki < 10 nM) while having minimal D2 occupancy, creating different interaction strengths with different receptor types. This selective local quality at specific receptor sites allows therapeutic effect without the broad-sided adverse effects of conventional agents that occupy multiple receptor pathways including D2, GABAA, and other systems.
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of gamma-carboline compounds to optimize their pharmacological profile. Specific structural modifications (such as the 4-phenyl-1-butanone substituent pattern) change the binding parameters to achieve potent 5-HT2A antagonism while reducing affinity for D2 receptors and other pathways. This parameter optimization transforms the compound from a broad-acting sedative into a selectively targeted agent.
2Reliability
If high occupancy of dopamine D2 pathways is achieved to treat central nervous system disorders, then therapeutic effects are obtained, but adverse effects such as drug dependency and muscle hypotonia occur
Solution Approach 1:
The patent applies the taking out principle by extracting the desired therapeutic function (5-HT2A antagonism) from the harmful mechanism (D2 pathway occupancy). The compound is designed to selectively target 5-HT2A receptors while explicitly avoiding significant interaction with D2 receptors. This extraction separates the beneficial therapeutic action from the harmful side effects that arise from dopamine pathway over-occupancy, eliminating drug dependency and muscle hypotonia while maintaining efficacy.
3Adaptability or versatility
If conventional agents are used to target multiple receptor pathways, then broad therapeutic coverage is achieved, but selectivity is reduced leading to more side effects
Solution Approach 1:
The patent applies inversion by reversing the conventional approach: instead of designing a compound that broadly occupies multiple receptor types (conventional approach), the invention designs a compound with highly selective 5-HT2A antagonism and explicitly minimized interaction with other pathways. This inverted strategy achieves precision targeting at 5-HT2A receptors while avoiding off-target effects, proving that selectivity can be maintained or even enhanced through careful molecular design rather than sacrificed for broad coverage.
Data Source
AI summary
The invention relates to a particular enantiomer of a substituted heterocycle fused gamma-carboline, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, and pathways involving the dopamine D1 and D2 receptor signaling system.